NASDAQ$LGVN
Longeveron Inc-A · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2021.
Longeveron Inc. reported revenue of $0.5 million and a net loss of $5.0 million for the second quarter of 2021. The company's cash on hand was $16.8 million, expected to be sufficient to cover expenses through at least the fourth quarter of 2022.
- Announced encouraging top-line results from Phase 2b Aging Frailty trial.
- Anticipate announcing top-line results from Phase 1/2 Aging Frailty “HERA” trial this quarter.
- Anticipate initiation of a Phase 2 Alzheimer’s disease trial and a Phase 2 Japan Aging Frailty trial later this year.
- First subject was dosed this past June in the Phase 2 Hypoplastic Left Heart Syndrome trial.
Headline financials
Revenue & EPS history
Longeveron · Revenue · Quarterly
$489K
Revenue by segment
Longeveron · $500K total across 1 segment · Q2 2021
- Clinical Trial Revenue$500K-44.4%100.0%
Forward guidance
Based on the Company’s current operating plan and financial resources, we believe that our existing cash on hand will be sufficient to cover expenses and capital requirements through at least the fourth quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
-5.1%
Avg return
Earnings day
-5.7%
Avg return
5 days after
+22.2%
Avg return
30 days after
35%
7 / 20 earnings
Positive
+10.0%
Q1 2022
Best reaction
-35.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -11.0% | +4.3% | |
| Q4 2025 | -4.7% | -0.7% | +6.1% | |
| Q3 2025 | -4.3% | -7.3% | -23.1% | |
| Q1 2025 | -10.1% | -9.4% | -17.4% | |
| Q4 2024 | -9.2% | -5.3% | +2.0% | |
| Q3 2024 | -2.3% | -8.8% | -14.3% | |
| Q2 2024 | -7.5% | -11.3% | -21.8% | |
| Q1 2024 | +3.1% | -1.5% | +106.9% | |
| Q4 2023 | +0.7% | +0.0% | -39.8% | |
| Q3 2023 | -6.7% | -0.5% | +17.6% | |
| Q2 2023 | -6.5% | -12.0% | -25.8% | |
| Q1 2023 | -6.1% | -11.9% | -0.9% | |
| Q4 2022 | -15.5% | -17.5% | -25.0% | |
| Q3 2022 | +5.1% | +2.6% | -14.1% | |
| Q2 2022 | +3.9% | +1.3% | -14.5% | |
| Q1 2022 | +10.0% | +16.2% | -0.7% | |
| Q4 2021 | -14.4% | -7.1% | +37.8% | |
| Q3 2021 | -4.9% | -15.6% | +461.6% | |
| Q2 2021 | -35.7% | -32.9% | -31.1% | |
| Q1 2021 | +1.7% | +17.9% | +35.8% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro